Cardinal Health, Inc. (CAH) - Fiscal 2024 Form 10-K Summary
Business Context and Reporting Period
This filing covers the fiscal year ended June 30, 2024. Cardinal Health is a global healthcare services and products company. Effective January 1, 2024, the company re-aligned its financial reporting structure into two reportable segments: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD). All other operating segments (Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics) are included in "Other."
The financial statements for fiscal 2024 and prior periods have been revised to correct an immaterial accounting error related to revenue recognition in the at-Home Solutions segment and other unrelated immaterial errors.
Key Financial Metrics
| Metric (in millions, except per share) | Fiscal 2024 | Fiscal 2023 | Fiscal 2022 |
|---|---|---|---|
| Revenue | $226,827 | $204,979 | $181,326 |
| Gross Margin | $7,414 | $6,874 | $6,484 |
| GAAP Operating Earnings | $1,243 | $752 | $(607) |
| Non-GAAP Operating Earnings | $2,414 | $2,076 | $1,973 |
| GAAP Diluted EPS | $3.45 | $1.26 | $(3.37) |
| Non-GAAP Diluted EPS | $7.53 | $5.85 | $5.07 |
| Net Cash from Operating Activities | $3,762 | $2,844 | $3,175 |
| Cash and Equivalents (End of Period) | $5,133 | $4,076 | $4,745 |
| Total Long-Term Obligations | $5,092 | $4,701 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 11% to $226.8 billion, driven primarily by branded and specialty pharmaceutical sales growth in the Pharma segment.
- Profitability: GAAP operating earnings increased 65% to $1.2 billion. This improvement was significantly aided by a reduction in goodwill impairment charges compared to the prior year ($675 million in 2024 vs. $1.2 billion in 2023).
- Segment Performance:
- Pharma: Revenue grew 11% and segment profit increased 7% to $2.0 billion, driven by the generics program.
- GMPD: Revenue increased 1% to $12.4 billion. Segment profit turned positive at $92 million (vs. a loss of $147 million in 2023) due to favorable comparisons to prior-year inflationary impacts.
- Goodwill Impairment: The GMPD segment's remaining goodwill balance of $90 million was fully impaired in Q3 2024 following a reallocation of goodwill due to the segment restructuring.
- Acquisitions: Completed the acquisition of Specialty Networks for $1.2 billion in cash in March 2024.
Guidance, Outlook, Risks, and Unusual Items
- OptumRx Contract Expiration: Pharmaceutical distribution contracts with OptumRx (17% of 2024 revenue) expired in June 2024. Management expects this to adversely impact fiscal 2025 results, including segment profit and operating cash flow due to the unwinding of negative net working capital.
- Opioid Litigation: The company has accrued $5.4 billion related to opioid litigation. Fiscal 2024 included a $340 million expense related to opioid matters, partially offset by a $105 million benefit from prepayments at a discount. Future payments are expected through 2038.
- Inflationary Pressures: GMPD segment profit continues to face inflationary impacts from transportation, commodities, and labor, though mitigation actions are expected to substantially offset these costs in fiscal 2025.
- Capital Deployment: The company deployed $750 million for share repurchases and $499 million for dividends in fiscal 2024. A $3.5 billion share repurchase program remains authorized through December 2027.
- Accounting Revisions: Prior period financial statements were revised to correct an immaterial revenue recognition error in the at-Home Solutions segment.
Investor Verification Checklist
- OptumRx Replacement: Verify the status of new contracts to replace the expired OptumRx revenue and the specific impact on working capital in fiscal 2025.
- Opioid Settlement Cash Flow: Confirm the schedule and magnitude of future opioid settlement payments and the adequacy of the $5.4 billion accrual.
- GMPD Goodwill: Monitor the GMPD segment's performance, as its goodwill is now fully impaired; future declines in fair value could impact other assets or indicate deeper operational issues.
- Specialty Networks Integration: Assess the integration progress and revenue contribution of the $1.2 billion Specialty Networks acquisition.
- Generic Program Volatility: Review the stability of the generics program, which is a key driver of Pharma segment profit but subject to pricing and volume fluctuations.